Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease

Next Previous
X
Search
Trial Profile

A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemvidutide (Primary)
  • Indications Non-alcoholic fatty liver disease; Obesity
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Altimmune

    • Most Recent Events

    • 25 Jul 2024 According to an Altimmune media release, Phase 1 trial extended for an additional 12 weeks, which resulted in up to 76.4% relative reduction in liver fat and further improvement in hepatic inflammation, and company look forward to publication of these data in the near future.
    • 25 Jul 2024 Results published in an Altimmune media release
    • 25 Jul 2024 According to an Altimmune media release, data from its 12-week clinical trial of pemvidutide, in metabolic dysfunction-associated steatotic liver disease has been published in the Journal of Hepatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top